CIK 0001321834
- Non-accelerated filer
- Smaller reporting company
Q/C TECHNOLOGIES, INC.
Sign in to watch- Ticker
- QCLS
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 856-848-8698
- Business address
- 1185 AVENUE OF THE AMERICAS, SUITE 249, NEW YORK, NY, 10036
- Former names
- Q/C TECHNOLOGIES, INC., TNF Pharmaceuticals, Inc., MyMD Pharmaceuticals, Inc., Akers Biosciences, Inc., Akers Biosciences Inc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-13 | Glass Mitchell Chief Medical Officer | Grant or award · Employee Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2025-11-14 | Glass Mitchell Director, Chief Medical Off. | Grant or award | +11,420 | 12,500 | ||
| 2025-10-03 | Glass Mitchell Director, Chief Medical Off. | Grant or award | +1,080 | 1,080 | ||
| 2025-04-17 | Glass Mitchell President, CMO | Grant or award · Employee Stock Option (Right to Buy) | +125,000 | 125,000 |
Page 1 of 1 · 4 trades